Paradigm Peptides, a research compound vendor based in Indiana, is closed following federal criminal charges. In December 2025, founder Matthew Kawa pleaded guilty in federal court to charges involving the sale of products containing a controlled substance. The website now displays a closure notice; no new orders are being accepted.

What the Charges Involved

The U.S. Attorney’s Office for the Northern District of Indiana found that products Paradigm sold as SARMs (selective androgen receptor modulators) actually contained testosterone — a scheduled controlled substance. Selling a controlled substance without authorization is a federal crime regardless of how the product is labeled.

Sentencing for Kawa was scheduled for March 24, 2026.

What This Means for Researchers

Paradigm Peptides’ closure follows the same pattern as Amino Asylum’s June 2025 raid: products sold as one compound contained a different, controlled compound. The underlying failure was inadequate independent verification.

Both cases make the same argument: when a vendor’s quality control depends entirely on internal processes, there is no external check preventing adulteration — intentional or otherwise. Independent third-party mass spectrometry testing is the only way to verify that a product contains what its label claims.

Where to Source Research Peptides After Paradigm

For researchers who used Paradigm for peptides: Paradigm’s peptide documentation was weaker than their SARM business — COAs were inconsistent and often internal. The shutdown, while disruptive, is an opportunity to upgrade to a supplier with independently verified documentation.

Life Link Research supplies research peptides with six-panel third-party COAs on every batch. For the GLP-1 peptides Paradigm stocked inconsistently (tirzepatide, semaglutide), LLR carries a complete range with verified documentation.

View Products →

FAQs

Is Paradigm Peptides still in business?

No. The website displays a closure notice. Following the federal guilty plea by the founder in December 2025, operations have ceased. No new orders are being fulfilled.

What happened to Paradigm Peptides’ founder?

Matthew Kawa pleaded guilty to federal charges in the Northern District of Indiana in December 2025. Sentencing was scheduled for March 24, 2026.

Were Paradigm Peptides’ peptide products affected by the charges?

The criminal charges specifically related to SARM products containing testosterone. Paradigm’s peptide product line’s integrity is not confirmed by the public charges. However, the systemic quality control failure raises questions about verification standards across the entire catalog.

What is the best Paradigm Peptides alternative?

For research peptides with independent COA verification: Life Link Research covers the core peptide range (BPC-157, semaglutide, tirzepatide, retatrutide, CagriSema) with fully independent third-party documentation. For SARMs, Paradigm’s closure has eliminated a major supplier; LLR does not supply SARMs.

For research purposes only. Not for human use.